ClinicalTrials.gg
CompletedNCT01018823Updated May 29, 2020

A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)

A Phase 1 interventional study of Ertugliflozin and Placebo to Ertugliflozin in Healthy Volunteer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of ertugliflozin.

Read the detailed description

To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics, of multiple oral doses of ertugliflozin.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.

(BMI) of 26.5 to 35.5 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion criteria

Exclusion Criteria:

Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Evidence of glycosuria, as defined by a positive urine dipstick test; Fasting (at least 10 hours) serum triglyceride >300 mg/dL; Fasting (at least 10 hours) LDL-cholesterol >190 mg/dL; Fasting (at least 10 hours) serum 25-OH Vitamin D concentration \<20 ng/mL

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Ertugliflozin 1 mg

    Ertugliflozin 1 mg, oral, once daily for 14 days

    Drug: Ertugliflozin

  • Experimental
    Ertugliflozin up to 5 mg

    Ertugliflozin up to 5 mg, oral, once daily for 14 days

    Drug: Ertugliflozin

  • Experimental
    Ertugliflozin up to 25 mg

    Ertugliflozin up to 25 mg, oral, once daily for 14 days

    Drug: Ertugliflozin

  • Experimental
    Ertugliflozin up to 100 mg

    Ertugliflozin up to 100 mg, once daily for 14 days

    Drug: Ertugliflozin

  • Placebo comparator
    Placebo

    Placebo to Ertugliflozin once daily for 14 days

    Drug: Placebo to Ertugliflozin

Interventions

  • Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast

    Also known as: PF-04971729, MK-8835

  • DrugPlacebo to Ertugliflozin

    Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing an Adverse Event (AE)

    Time frame: Up to 28 days postdose (Up to 42 days)

  2. Number of Participants Discontinuing Study Drug Due to an AE

    Time frame: Up to 14 days

  3. Area under the plasma concentration-time curve (AUC) over the dosing interval tau (AUCtau) for ertugliflozin

    Time frame: Up to 17 days

  4. Maximum plasma concentration (Cmax) of ertugliflozin

    Time frame: Up to 17 days

  5. Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin

    Time frame: Up to 17 days

  6. Ertugliflozin half life (t1/2)

    Time frame: Up to 17 Days

  7. Apparent clearance (CL/F) after a single dose of ertugliflozin

    Time frame: Up to 17 days

  8. Apparent volume of distribution (Vz/F)

    Time frame: Up to 17 days

  9. Observed Accumulation Ratio of Area Under the Curve for the dosing interval of ertugliflozin (Rac[obs])

    Time frame: Up to 17 days

  10. Change from baseline in 24-hour weighted mean glucose

    Time frame: Baseline and Day 14

  11. Change from baseline in 24-hour urinary glucose excretion

    Time frame: Baseline and Day 14

  12. Change from baseline in 24-hour plasma C-peptide

    Time frame: Baseline and Day 14

  13. Inhibition of glucose reabsorption

    Time frame: Baseline and Day 14

  14. Change from baseline in body weight

    Time frame: Baseline and Day 14

  15. Area under the plasma concentration-time curve over 8 hours (AUC[0-8]) for serum intact parathyroid hormone

    Time frame: Up to 17 days

  16. Area under the plasma concentration-time curve over 24 hours (AUC[0-24]) for serum intact parathyroid hormone

    Time frame: Up to 17 days

  17. Trough concentration of serum intact parathyroid hormone (Ctrough)

    Time frame: Up to 17 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Fediuk DJ, Nucci G, Dawra VK, Cutler DL, Amin NB, Terra SG, Boyd RA, Krishna R, Sahasrabudhe V. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. Clin Pharmacokinet. 2020 Aug;59(8):949-965. doi: 10.1007/s40262-020-00875-1. PubMed 32337660 ↗
  • Marshall JC, Liang Y, Sahasrabudhe V, Tensfeldt T, Fediuk DJ, Zhou S, Krishna R, Dawra VK, Wood LS, Sweeney K. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure. J Clin Pharmacol. 2021 Sep;61(9):1220-1231. doi: 10.1002/jcph.1866. Epub 2021 Jun 19. PubMed 33813736 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2009 to primary completion in Mar 2010, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2009
First posted
Nov 25, 2009
StartActual
Dec 14, 2009
Primary completionActual
Mar 18, 2010
CompletionActual
Mar 18, 2010
Last update
May 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01018823
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Nov 25, 2009
Start date
Dec 14, 2009
Primary completion
Mar 18, 2010
Completion
Mar 18, 2010
Last update
May 29, 2020

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion